Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Gastroenterology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT06414057

HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks

HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks — Recruiting • Oncology • NCT06414057.

📅 08 Apr 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06414057
Sponsor
University of Edinburgh
Start
2025-07-07
ClinicaliQ Trial Snapshot
  • HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks — Recruiting • Oncology • NCT06414057.
  • Individuals with experience of homelessness, substance use/addiction, transactional sex, and incarceration experience significant health inequities across a wide range of health conditions. This inequity includes cervical cancer with individuals in these populations less engaged with both routine human papillomavirus (HPV) vaccination and….
  • Sponsor: University of Edinburgh.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Individuals with experience of homelessness, substance use/addiction, transactional sex, and incarceration experience significant health inequities across a wide range of health conditions. This inequity includes cervical cancer with individuals in these populations less engaged with both routine human papillomavirus (HPV) vaccination and cervical cancer screening programmes, yet also at higher risk of developing cervical cancer. Opportunistic vaccination is recommended by the Joint Committee on Vaccination and Immunisation for 'other at risk/vulnerable groups' who may benefit (such as people with experience of transactional sex or incarceration) at clinical discretion. However, there…

Eligibility Snapshot
  • : Individuals will be eligible for participation in components 1 and/or 2 if they: * have a cervix * are aged 25-45 years (inclusive) * are able to provide informed consent for themself And have experience of either: * substance use/addiction * living in custodial settings * homelessness * involvement in transactional sex

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)
Oncology · 17 Mar 2026
I appreciate your request, but I need to be transparent: the content provided only includes the title, metadata, and editorial notes -…
View guideline →
Clinical Brief
Ultrasound delays putting pregnant women and cancer patients at risk, sonographers say
Oncology · BBC Health · 28 Mar 2026
Ultrasound service capacity is insufficient due to inadequate sonographer training, creating delays that compromise care for pregnant women and cancer patients requiring…
View brief →
Clinical Brief
Women attending first NHS mammogram hits 10-year high as thousands more cancers found
Oncology · NHS England · 19 Feb 2026
Hundreds of thousands more women attended NHS breast screening last year and thousands more cancers were diagnosed early in England. New figures…
View brief →
Guideline
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma
Oncology · 21 Apr 2026
Pembrolizumab is recommended as neoadjuvant treatment prior to surgery for resectable locally advanced head and neck squamous cell carcinoma, followed by adjuvant…
View guideline →
Guideline
Ovarian Cancer: Recognition and Initial Management (NICE NG241)
Oncology · 27 Mar 2026
Perform CA125 blood test and pelvic ultrasound (including ovarian assessment) as first-line investigations in primary care when ovarian cancer is suspected based…
View guideline →
Guideline
Prostate Cancer: Diagnosis and Management (NICE NG131)
Oncology · 27 Mar 2026
Offer PSA testing to men aged 50–69 years after informed discussion of benefits and harms; consider testing men aged 40–49 with family…
View guideline →